PMID- 23176691
OWN - NLM
STAT- MEDLINE
DCOM- 20130506
LR  - 20221109
IS  - 1744-8298 (Electronic)
IS  - 1479-6678 (Linking)
VI  - 8
IP  - 6
DP  - 2012 Nov
TI  - The impact of current and novel anti-diabetic therapies on cardiovascular risk.
PG  - 895-912
LID - 10.2217/fca.12.68 [doi]
AB  - Type 2 diabetes mellitus (T2DM) has become an overwhelming health condition that 
      is no longer just a threat to developed nations, but to undeveloped nations as 
      well. Current therapies for T2DM are relatively effective in controlling 
      hyperglycemia; examples include metformin, thiazolidinediones, sulfonylurea 
      derivatives, alpha-glucosidase inhibitors, glucagon-like peptide-1 receptor agonists 
      and dipeptidyl peptidase-4 inhibitors. Despite their efficacy in controlling 
      hyperglycemia, due to recent findings of increased cardiovascular risk following 
      treatment with either rosiglitazone or intensive glucose lowering, new guidelines 
      from the US FDA recommend that new therapies for diabetes not only improve 
      glycemia, but exert no adverse cardiovascular effects. Based on cardiovascular 
      risk profiles, metformin appears to be the superior anti-diabetic therapy, 
      although studies in humans with glucagon-like peptide-1 receptor agonists are 
      encouraging. As patients with T2DM also often have cardiovascular disease, the 
      increased rigor in drug development should ultimately reduce the health burden of 
      both of these conditions.
FAU - Ussher, John R
AU  - Ussher JR
AD  - Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, 
      Canada. ussher@lunenfeld.ca
FAU - Sutendra, Gopinath
AU  - Sutendra G
FAU - Jaswal, Jagdip S
AU  - Jaswal JS
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Future Cardiol
JT  - Future cardiology
JID - 101239345
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/*complications
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Metformin/therapeutic use
EDAT- 2012/11/28 06:00
MHDA- 2013/05/07 06:00
CRDT- 2012/11/27 06:00
PHST- 2012/11/27 06:00 [entrez]
PHST- 2012/11/28 06:00 [pubmed]
PHST- 2013/05/07 06:00 [medline]
AID - 10.2217/fca.12.68 [doi]
PST - ppublish
SO  - Future Cardiol. 2012 Nov;8(6):895-912. doi: 10.2217/fca.12.68.